Biography

Joel Lewis is Chief Executive Officer (CEO) and President of Galectin Therapeutics. In this position, Mr. Lewis sets corporate strategy and oversees operations, most importantly Galectin’s global NASH-RX adaptively-designed trial for the prevention of varices in NASH cirrhosis patients using its proprietary galectin-3 inhibiting compound, belapectin (GR-MD-02). Mr. Lewis has served on the Board of Directors for Galectin Therapeutics since 2017 and was previously chair of the Audit Committee. Mr. Lewis is a financial executive with over 25 years of experience, who began his career in public accounting in 1992. From 2007 through 2019, Mr. Lewis acted as the Managing Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies). Prior to his employment with Uline Inc., Mr. Lewis served as a Tax and Accounting Manager for Century America LLC from 2001 to 2006 and a Tax Manager for Deloitte & Touche from 1998 to 2001. Mr. Lewis has a wide range of expertise including working in a variety of industries and disciplines including taxation, restructuring, acquisition and private equity ventures. Mr. Lewis is a registered CPA in the state of Illinois. He holds a B.S. in Accountancy from the University of Illinois and a Masters in Taxation from DePaul University.